MGX
Metagenomi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.10
−2.65%2
Insider buys (3m)
3
Insider sells (3m)
$18.3K
Net value (3m)
-6.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 11, 2026 | Reid Laurence · director | Purchase | 117 | $1.18 |
| Sep 11, 2026 | Reid Laurence · director | Purchase | 19,883 | $1.17 |
| Sep 10, 2026 | Wapnick Pamela · officer: Chief Financial Officer | Sale | 1,911 | $1.16 |
| Sep 10, 2026 | Irish Jian · director, officer: See Remarks | Sale | 2,140 | $1.16 |
| Sep 10, 2026 | Wein Matthew · officer: See Remarks | Sale | 358 | $1.16 |
| Jun 11, 2026 | Eckhardt Juergen · director | A-Award | 21,000 | $1.23 |
| Jun 11, 2026 | Reid Laurence · director | A-Award | 17,400 | $1.23 |
| Jun 11, 2026 | Dere Willard H · director | A-Award | 21,000 | $1.23 |
| Jun 11, 2026 | BJERKHOLT ERIC · director | A-Award | 21,000 | $1.23 |
| Jun 10, 2026 | Wapnick Pamela · officer: Chief Financial Officer | Sale | 2,884 | $1.30 |
| Jun 10, 2026 | Irish Jian · director, officer: See Remarks | Sale | 3,737 | $1.30 |
| Jun 10, 2026 | Wein Matthew · officer: See Remarks | Sale | 558 | $1.30 |
| Apr 3, 2026 | Wapnick Pamela · officer: Chief Financial Officer | A-Award | 144,000 | $1.34 |
| Apr 3, 2026 | Wapnick Pamela · officer: Chief Financial Officer | A-Award | 24,000 | $0.00 |
| Apr 3, 2026 | Wein Matthew · officer: See Remarks | A-Award | 68,000 | $1.34 |
| Apr 3, 2026 | Wein Matthew · officer: See Remarks | A-Award | 11,000 | $0.00 |
| Apr 3, 2026 | Irish Jian · director, officer: See Remarks | A-Award | 276,000 | $1.34 |
| Apr 3, 2026 | Irish Jian · director, officer: See Remarks | A-Award | 46,000 | $0.00 |
| Mar 9, 2026 | Wapnick Pamela · officer: Chief Financial Officer | Sale | 1,581 | $1.60 |
| Mar 9, 2026 | Wein Matthew · officer: See Remarks | Sale | 482 | $1.60 |
| Mar 9, 2026 | Irish Jian · director, officer: Chief Executive Officer | Sale | 1,607 | $1.60 |
| Dec 8, 2025 | Wapnick Pamela · officer: Chief Financial Officer | Sale | 1,576 | $1.77 |
| Dec 8, 2025 | Irish Jian · director, officer: Chief Executive Officer | Sale | 1,602 | $1.77 |
| Dec 8, 2025 | Wein Matthew · officer: See Remarks | Sale | 199 | $1.77 |
| Dec 8, 2025 | Thomas Brian C. · director | Sale | 3,830 | $1.77 |
| Dec 1, 2025 | Wein Matthew · officer: See Remarks | Sale | 199 | $1.81 |
| Dec 1, 2025 | Wapnick Pamela · officer: Chief Financial Officer | A-Award | 120,000 | $1.60 |
| Dec 1, 2025 | Wapnick Pamela · officer: Chief Financial Officer | Sale | 1,576 | $1.81 |
| Dec 1, 2025 | Irish Jian · director, officer: Chief Executive Officer | A-Award | 211,000 | $1.60 |
| Dec 1, 2025 | Irish Jian · director, officer: Chief Executive Officer | A-Award | 37,500 | $1.60 |
Institutional positioning
13F filings over the trailing two quarters
New 9Increased 21Reduced 28Sold out 8
| Filer | Action | Shares | Filed |
|---|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 1,077,700 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 1,057,944 | May 15, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Increased | 787,900 | May 14, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Reduced | 742,400 | Aug 13, 2026 |
| Catalio Capital Management, LP | Unchanged | 528,993 | Aug 14, 2026 |
| CATALIO CAPITAL MANAGEMENT, LP | Unchanged | 528,993 | May 15, 2026 |
| Peapod Lane Capital LLC | Increased | 525,024 | Jul 27, 2026 |
| PEAPOD LANE CAPITAL LLC | Increased | 516,761 | May 4, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 513,701 | Aug 14, 2026 |
| TWO SIGMA INVESTMENTS, LP | Increased | 496,767 | May 15, 2026 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | Increased | 400,300 | Aug 14, 2026 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | Unchanged | 395,800 | May 15, 2026 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | New Position | 382,153 | May 15, 2026 |
| WELLS FARGO & COMPANY/MN | Increased | 379,508 | Aug 14, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 358,200 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 11, 2026